Magnetar Financial’s CRISPR Therapeutics CRSP Stock Holding History

Magnetar Financial’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-6,556	Closed	-$319K	–	945
2025 Q2	$319K	Buy	+6,556	New	+$254K	﹤0.01%	683
2025 Q1	–	Sell	-9,125	Closed	-$359K	–	769
2024 Q4	$359K	Buy	+9,125	New	+$431K	0.01%	434
2023 Q4	–	Sell	-14,533	Closed	-$660K	–	409
2023 Q3	$660K	Buy	14,533 +6,971	+92%	+$360K	0.02%	294
2023 Q2	$425K	Hold	7,562	–	–	0.01%	362
2023 Q1	$342K	Sell	7,562 -1,872	-20%	-$90.9K	0.01%	499
2022 Q4	$383K	Sell	9,434 -3,092	-25%	-$164K	0.01%	641
2022 Q3	$819K	Sell	12,526 -545	-4%	-$39.5K	0.01%	752
2022 Q2	$794	Buy	13,071 +5,236	+67%	+$308K	0.01%	1038
2022 Q1	$492K	Buy	+7,835	New	+$492K	0.01%	919

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Magnetar Financial's CRSP Position: Q3 2025 in Review

Magnetar Financial sold out of CRISPR Therapeutics (CRSP) in Q3 2025, closing a stake of 6,556 shares — an estimated $319K sold.

Magnetar Financial first reported a position in CRSP in Q1 2022 and held it in 9 quarters. The position peaked at $819K in Q3 2022. 440 funds tracked by Wall St. Rank hold CRSP as of Q3 2025.

Magnetar Financial reported no remaining CRISPR Therapeutics position as of Q3 2025 after selling out during the quarter.
Magnetar Financial sold 6,556 CRISPR Therapeutics shares in Q3 2025, an estimated $319K.
Magnetar Financial first reported a position in CRISPR Therapeutics in Q1 2022 and held it in 9 quarters.
Magnetar Financial's CRISPR Therapeutics position peaked at $819K in Q3 2022.
440 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2025.

Based on Magnetar Financial's 13F filing for Q3 2025, filed 13 Nov 2025.